CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 211 enrolled
Drug / intervention
ESS305 (Essure, BAY1454032) +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01740687
NCT01740687N/ACompleted

A Study to Evaluate the Effectiveness of Essure Post-NovaSure Radiofrequency Endometrial Ablation Procedure Following a Successful Essure Confirmation Test

Bayer·observational·Posted Dec 4, 2012·Updated Feb 6, 2023

In Brief

An observational study evaluating ESS305 (Essure, BAY1454032) and NovaSure for Contraception and Menorrhagia. Completed, enrolled 211 participants across 17 sites.

Detailed Summary

The purpose of the post approval study is to evaluate the effectiveness and safety of the Essure System when a NovaSure Endometrial Ablation procedure is performed following a successful Essure Confirmation Test.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedDec 4, 2012
Enrollment StartNov 13, 2012
Primary CompletionMay 17, 2021
Study CompletionJun 14, 2021
TodayJul 2, 2026
Enrollment to primary: 8.5 yearsPosted 13.6 years ago

Interventions

ESS305 (Essure, BAY1454032)device

Essure Permanent Birth Control

NovaSureprocedure

Nova Sure Endometrial Ablation